For on-demand treatment of acute hereditary angioedema (HAE) attacks
Be prepared for an HAE attack. Be prepared with BERINERT.
BERINERT is the only on-demand treatment offering:
Median onset of laryngeal
attack relief: 15 minutes
Median onset of laryngeal attack relief: 15 minutes
Single dose,
rapid uptake*
Approved use
in pediatrics†
More than 50% of people with HAE may experience a laryngeal attack in their lifetime1
Following self-administration of BERINERT for laryngeal HAE attacks, advise patients to immediately seek medical attention.
*
In a prospective, randomized, open-label, crossover study, 23 subjects with mild or moderate HAE received a single dose of BERINERT (1000 units) IV or SC during an attack-free interval.2
†BERINERT is the only C1-INH approved for on-demand treatment of acute abdominal, facial or laryngeal attacks of HAE in adults and pediatric patients.
Get your patients started on BERINERT
Prescribe BERINERT and empower them to self-administer at the first sign
of an HAE attack.
Get started
Have additional questions?
Connect with CSL Behring Medical Affairs to find additional information and ask questions.
HAE causes unpredictable and often painful attacks of swelling
References: 1. Zuraw BL. Clinical practice: hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036.
2. Martinez-Saguer I, Cicardi M, Suffritti C, et al. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Transfusion. 2014;54:1552-1561.
3. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161(20):2417-2429.
4. Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):264-274.